How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?. (15th September 2017)

• Record Type: Journal Article
• Authors: McKee, Amy E.; Markon, André O.; Chan‐Tack, Kirk M.; Lurie, Peter
• Other Names: Lee Lucy guestEditor.; Lewis Lionel D. guestEditor.
• Is Part Of: Journal of clinical pharmacology. Volume 57(2017)Supplement 10
• Page Start: S136
• Page End: S142
• Publication Date: 2017-09-15
• Subjects: expanded access -- compassionate use -- US Food and Drug Administration; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.960
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: In this review of individual patient expanded‐access requests to the Center for Drug Evaluation and Research for the period Fiscal Year 2010 to Fiscal Year 2014, we evaluated the number of applications received and the number allowed to proceed. We also evaluated whether drugs and certain biologics obtained under expanded access went on to be approved by the Food and Drug Administration. Finally, we considered concerns that adverse events occurring during expanded access might place sponsors at risk for legal liability. Overall, 98% of individual patient expanded‐access requests were allowed to proceed. During the study period, among drugs without a previous approval for any indication or dosage form, 24% of unique drugs (ie, multiple applications for access to the same drug were considered to relate to 1 unique drug), and 20% of expanded‐access applications received marketing approval by 1 year after initial submission; 43% and 33%, respectively, were approved by 5 years after initial submission. A search of 3 legal databases and a database of news articles did not appear to identify any product liability cases arising from the use of a product in expanded access. Our analyses seek to give physicians and patients a realistic perspective on the likelihood of a drug's approval as well as certain information regarding the product liability risks for commercial sponsors when providing expanded access to investigational drugs. The US Food and Drug Administration (FDA)'s expanded‐access program maintains a careful balance between authorizing patient access to potentially beneficial drugs and protecting them from drugs that may have unknown risks. At the same time, the agency wishes to maintain the integrity of the clinical trials process, ultimately the best way to get safe and effective drugs to patients.